SS
CPRX

Steve Schonfeld’s Catalyst Pharmaceutical CPRX Stock Holding History

Steve Schonfeld’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$786K Buy
+25,000
New +$738K ﹤0.01% 1617

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steve Schonfeld's CPRX Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 127,302 shares worth $4M. The stake represents 0.01% of the portfolio and ranks #739 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in CPRX as recently as Q1 2025.

Steve Schonfeld first reported a position in CPRX in Q4 2017 and has held it in 7 quarters since. 392 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Steve Schonfeld held 127,302 shares of Catalyst Pharmaceutical worth $4M as of Q2 2026.
  • Catalyst Pharmaceutical was a new Steve Schonfeld position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #739 holding.
  • Steve Schonfeld first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 7 quarters since.
  • 392 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.